The estimated Net Worth of Michelle R Ryan is at least $118 millier dollars as of 31 August 2023. Michelle Ryan owns over 1,000 units of Catalent stock worth over $118,008 and over the last few years Michelle sold CTLT stock worth over $0.
Michelle has made over 1 trades of the Catalent stock since 2023, according to the Form 4 filled with the SEC. Most recently Michelle bought 1,000 units of CTLT stock worth $49,980 on 31 August 2023.
The largest trade Michelle's ever made was buying 1,000 units of Catalent stock on 31 August 2023 worth over $49,980. On average, Michelle trades about 333 units every 0 days since 2023. As of 31 August 2023 Michelle still owns at least 1,979 units of Catalent stock.
You can see the complete history of Michelle Ryan stock trades at the bottom of the page.
Michelle's mailing address filed with the SEC is C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET, NJ, 08873.
Over the last 10 years, insiders at Catalent have traded over $2,686,980,380 worth of Catalent stock and bought 123,000 units worth $5,376,345 . The most active insiders traders include Management Associates V L.L..., Peter Zippelius et Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of $22,866,018. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth $39,429.
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
Catalent executives and other stock owners filed with the SEC include: